Back to search
FDAFDA · Food and drugs·Recall number D-0090-2023

Ganciclovir for Injection, USP, 500mg per vial, packaged in a 10-count carton, Rx Only, Mfd. by: THYMOORGAN PHARMAZIE GmbH, Germany, Distributed by Hikma Berkeley Heights, NJ 07922, NDC 0143-9299-01

Published January 4, 2023 · Recall initiated: December 16, 2022

Summary

FDA records drug Class II recall D-0090-2023, published January 4, 2023 and initiated December 16, 2022. Recalling firm: Hikma Pharmaceuticals USA Inc.; Status: Terminated; Reported quantity: 13,760 vials; Lot: Lot#: BQ0006, Exp 08/2023. Class II means possible temporary or medically reversible effects, or a remote probability of serious health consequences.

Status when published: Terminated — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

Labeling: Label mix-up - one vial was mislabeled as Cladribine Injection 10mg/mL inside a 10-count carton of Ganciclovir 500 mg.

What to do

Voluntary: Firm initiated

Get an email if GANCICLOVIR has another recall

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Brand
GANCICLOVIR
Manufacturer
Hikma Pharmaceuticals USA Inc.
Distributor
USA Nationwide
Lot
Lot#: BQ0006, Exp 08/2023
Risk classification
Class II
Area (FDA)
drug
Country
United States

Related recalls

Questions about this recall

Was Ganciclovir for Injection, USP, 500mg per vial, packaged in a 10-count carton, Rx Only, Mfd. by: THYMOORGAN PHARMAZIE GmbH, Germany, Distributed by Hikma Berkeley Heights, NJ 07922, NDC 0143-9299-01 recalled?

Yes. FDA published recall D-0090-2023 on January 4, 2023. Reported hazard: Labeling: Label mix-up - one vial was mislabeled as Cladribine Injection 10mg/mL inside a 10-count carton of Ganciclovir 500 mg.

What should I do if I have this product?

Voluntary: Firm initiated

How do I know if my unit is part of the recall?

Compare your product details with the notice. Brand: GANCICLOVIR.